AstraZeneca Launches New Health-Tech Business To Accelerate Trials
As the need for speed continues to drive innovation across the pharmaceutical ecosystem, AstraZeneca has launched a new stand-alone business dedicated to globally-scaled digital health solutions. The new company, called Evinova, is “set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.”
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “The future of medicine development can be accelerated with digital solutions. We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale, provides a real opportunity to fundamentally improve patient care, drive healthcare transformation and reduce carbon emissions.”
Cristina Duran, President of Evinova, said: “We are excited to bring the portfolio of globally-scaled digital solutions developed to serve AstraZeneca’s drug development pipeline to the wider life sciences community. We believe this will help propel the sector forward in digital health, as we know healthcare professionals and regulators need digital solutions that work across pharma and support patients broadly. Coming from within the sector and with proven experience, Evinova will be uniquely placed to deliver science-based, evidence-led and human experience-driven solutions with the aim of improving patient experience and outcomes.”
Globally-leading CROs Parexel and Fortrea have entered into agreements to offer Evinova digital health solutions to their wide customer base. To accelerate industry adoption and sustain and expand the global reach of its digital products, Evinova is collaborating with Accenture and Amazon Web Services.
This move comes at a pivotal moment in the evolution of drug discovery as data and AI increasingly move to the center of the entire drug development process. Industry observers will be closely watching the progress that Evinova is able to make as a stand-alone business in this rapidly changing space.
